您现在的位置: 首页> 研究主题> 常规分割

常规分割

常规分割的相关文献在1989年到2021年内共计72篇,主要集中在肿瘤学、中国医学、内科学 等领域,其中期刊论文70篇、会议论文1篇、专利文献28405篇;相关期刊48种,包括股市动态分析、卫生职业教育、内蒙古中医药等; 相关会议1种,包括第二届国际中西医结合、中医肿瘤学术研讨会等;常规分割的相关文献由244位作者贡献,包括倪雪莉、冯活林、庞学利等。

常规分割—发文量

期刊论文>

论文:70 占比:0.25%

会议论文>

论文:1 占比:0.00%

专利文献>

论文:28405 占比:99.75%

总计:28476篇

常规分割—发文趋势图

常规分割

-研究学者

  • 倪雪莉
  • 冯活林
  • 庞学利
  • 彭开桂
  • 李梅坤
  • 李涛
  • 王一鸣
  • 王鹤皋
  • 蔡晶
  • 郎锦义
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 李敏杰; 黄平平
    • 摘要: 目的 分析基于体膜开窗定位方式的乳腺癌保乳术后大分割放疗和常规分割放疗患者的不良反应、美容效果,对改良定位方式进行探讨.方法 前瞻性对2019年1月至2020年4月收治的75例乳腺癌保乳术后患者,采用随机数字表法分为两组:大分割组,38例,42.4 Gy/16次,2.65 Gy/次;常规组,37例,50 Gy/25次,2.0 Gy/次.均采用热塑体膜定位,并沿患侧乳腺根部将乳房上方体膜剪去.观察两组的不良反应、美容效果及随访生存情况.结果 随访期间,两组患者8个月内无复发病例,局部控制率100%,生存率100%.两组患者急性皮肤反应总发生率为大分割组36.84% (14/38)和常规组67.57% (25/37),差异有统计学意义(x2=7.09,P<0.05);美容效果优良率为大分割组89.47% (34/38)和常规组78.38% (29/37),但差异无统计学意义(P>0.05);白细胞减少、血小板减少及晚期皮肤反应差异无统计学意义(P>0.05).结论 基于体膜开窗定位方式的乳腺癌保乳术后大分割放疗方案具有可行性,可明显减轻急性放射性皮肤反应,且并未增加放疗不良反应.但长期效果仍需长期随访研究来证实.
    • 郭逸潇; 胡金炎; 李洋; 王宁; 缪国英; 李波
    • 摘要: 对比了aSi-1200 EPID与Octavius 729探测器在常规分割非均整(Flattening filter free,FFF)部分弧RapidArc计划验证中的应用,探究两者的适用性和局限性及对MLC(Multi-leaf collimator)模型参数变化的γ响应.获取水模体不同大小方野的通量图,比较通过中心轴Crossline和Inline的CU(Calibration unit)值曲线评估aSi-1200 EPID背向散射屏蔽层的有效性.选取50个计划,在不同标准和阈值行2Dγ指数通过率分析(全局归一),将γ值较低的计划数据导入Verisoft软件重建剂量.任选一计划,引入不同量值的MLC透射因子(Transmission factor,TF)和剂量叶片间隙(Dosimetric leaf gap,DLG)偏差,共创建80个修正剂量分布,将原始计划的测量剂量与修正计划的TPS剂量行γ通过率评估.结果表明:正的离轴位置跌落区CU值差异达2~3倍,Inline方向测量值整体偏小(Varian EDGE加速器),而Halcyon加速器两个方向CU值轮廓近乎完全重合.aSi-1200 EPID的γ通过率中值和均值均高于Octavius 729矩阵,基于Octavius 729和Octavius 1500矩阵测量重建的剂量与TPS对比部分剂量学偏差DD%:PGTV的D98%(?9.60%,?14.30%),Heart的V30(?6.80%,?2.36%),Lung L的V30(?8.11%,15.79%),Lung R的V30(100%,50%),Cord的Dmax(3.55%,?0.82%).随着TF和DLG偏离TPS预设值的增加,两种方式得到的γ通过率在数值上均未呈现下降的趋势.提出了一种测试医用电子直线加速器电子射野影像系统(EPID)探测板背散射屏蔽层效果的方法.Octavius 729和aSi-1200 EPID所使用软件计算的γ通过率无法可靠地识别引入误差的MLC射束模型,这些结果为解释IROC-H(Imaging and radiation oncology core houston quality assurance center)体模试验的高失败率提供了参考.
    • 汤忠明; 黄乃信; 郭恒照
    • 摘要: 目的 探析对于早期鼻咽癌患者采用后程加速超分割放射治疗的临床疗效.方法 26例早期鼻咽癌患者,随机分为观察组与对照组,每组13例.对照组采用常规分割放射治疗,观察组采用后程加速超分割放射治疗,观察并比较两组患者放疗后3个月临床治疗效果;比较两组患者随访时晚期损伤(口干、耳聋、张口困难、颈部纤维化、放射性脑病)的发生情况.结果 放疗后3个月,观察组患者治疗总有效率为92.31%,高于对照组的53.85%,差异具有统计学意义(P0.05).结论 在早期鼻咽癌的临床治疗上,采用后程加速超分割放射治疗可获得理想效果,临床疗效显著并,从而降低晚期损伤发生率,可提升患者的生存质量,值得推广和应用.
    • 朱海文; 于静萍; 汪建林; 蒋友芹; 裴冬; 王坚
    • 摘要: 目的 探讨大分割放疗(HFR)联合紫杉醇周剂量化疗治疗食管癌术后气管食管沟淋巴结(TGLN)的安全性和疗效.方法 将53例食管癌术后单纯TGLN转移的患者随机抛硬币法分为两组,大分割组25例采用60 Gy/20次放疗,常规分割组28例采用60 Gy/30次放疗,两组患者放疗同时均采用紫杉醇50 mg周剂量化疗.比较两种不同分割方式对不良反应及预后的影响.结果大分割组和常规分割组患者3~4级放射性食管炎、 肺炎发生率分别为44.0% 、16.0% 和25.0% 、7.1%,两组比较差异无统计学意义(P>0.05).两组近期有效率比较,差异无统计学意义(P>0.05).淋巴结转移灶直径≤2 cm患者近期有效率高于淋巴结转移灶直径>2 cm的患者(P<0.05).大分割组和常规分割组中位总生存期(OS)分别为24.2个月(95%CI 16.2~32.1)和11.8个月(95%CI 9.2~14.4),两组比较差异有统计学意义(χ2=5.063,P<0.05).单因素和多因素分析均显示淋巴结直径和分割方式是影响患者预后的因素(P<0.05).结论 大分割放疗联合紫杉醇周剂量化疗治疗食管癌术后气管食管沟淋巴结较常规分割提高了患者预后,且治疗并发症未明显增加.
    • 吕家华; 刘涛; 李涛; 李昉; 王俊超; 杨川; 张军; 王捷; 郎锦义
    • 摘要: Objective To investigate the clinical efficacy and safety of preoperative hypofractionated and conventionally-fractionated chemoradiotherapy for thoracic esophageal cancer. Methods A total of 86 patients with thoracic esophageal cancer receiving chemoradiotherpy in Sichuan Cancer Hospital between 2002 and 2011 were enrolled and randomized into the preoperative hypofractionated chemoradiotherapy group ( group A, n=41, 30 Gy in 10 fractions for 2 weeks ) and conventionally-fractionated chemoradiotherapy group ( group B, n=45, 40 Gy in 20 fractions for 4 weeks ) . Surgery was performed at 2-6 weeks after chemoradiotherapy. The probability of patients' survival was estimated by Kaplan-Meier method and analyzed by log-rank test. Results In groups A and B, the pathological downstaging rates were 68% and 56%( P=0. 270) , the R0 resection rates were 95% and 89%( P=0. 437) and the pCR rates of 32% and 24%( P=0. 480).The 1-,3-and 5-year overall survival (OS) rates were 78% and 69%,44% and 44%,29% and 33%(P=0. 114,0. 223,0. 289), and the progression-free survival (PFS) rates were 71% and 62%,39% and 38%,24% and 29%(P=0. 211,0. 689,0. 331), respectively. The incidence rate of chemoradiothery-and surgery-related adverse events did not differ between two groups (P=0. 089-0. 872).The average length of hospital stay, radiotherapy cost and preoperative treatment costs in group A were significantly less compared with those in group B (P=0. 000,0. 000,0. 000). Conclusions Both preoperative hypofractionated and conventionally-fractionated chemoradiotherapy can be used as the regimen of preoperative chemoradiotherapy in patients with resectable thoracic esophageal carcinoma. Compared with conventionally-fractionated chemoradiotherapy, preoperative hypofractionated chemoradiotherapy has shorter treatment cycle, shorter length of hospital stay and lower radiotherapy cost, which is more easily accepted by patients.%目的 评价术前大分割放疗与常规分割放疗治疗胸段食管鳞癌的疗效和安全性.方法2002—2011年四川省肿瘤医院收治的行术前放化疗的胸段食管鳞癌共86例,根据术前放疗分割方式分为大分割放疗组(A组,41例,30 Gy分10次2周)和常规分割放疗组(B组,45例,40 Gy分20次4周),放疗结束后2—6周手术.Kaplan-Meier法计算生存并Logrank检验.结果A组与B组病理降期率分别为68%和56%(P=0.270),R0切除率分别为95%和89%(P=0.437),pCR率分别为32%和24%(P=0.480).A组和B组1、3、5年OS分别为78%和69%、44%和44%,29%和33%(P=0.114、0.223、0.289),PFS分别为71%和62%、39%和38%、24%和29%(P=0.211、0.689、0.331).两组患者放化疗和手术相关不良反应相近(P=0.089~0.872).大分割放疗组在平均住院天数、放疗费用及术前治疗总费用上均明显低于常规放疗组(P=0.000、0.000、0.000).结论术前大分割放疗和常规放疗均可作为可切除胸段食管鳞癌术前放疗的选择方案.术前大分割放疗有治疗周期和住院时间短,放疗费用低,患者更易接受的优势.
    • 摘要: 目的 探讨对常规分割模式下胸部肿瘤适形和调强放疗技术进行脊髓生物效应剂量(BED)评估的必要性和可行性.方法 选取2016年5月16日至2016年12月31日于唐山市人民医院放化疗科收治的胸部肿瘤患者30例,应用医诺RTIS治疗计划评估模块对所有患者的治疗计划进行评估,并进行物理剂量(PhD)和BED的比较.依据线性二次方程(L-Q模型)计算2.0 Gy照射1次和30次时脊髓在不同剂量曲线的PhD和RED.组间比较采用t检验.结果 脊髓的RED曲线位于PhD曲线左侧,计划靶体积(PTV)的BED曲线位于PhD曲线右侧.30例患者的治疗计划中,脊髓的最小、最大、平均PhD与BED分别为(80.41±274.75)、(3398.00±1200.95)、(1265.79±762.49) cGy和(74.71±249.34)、(3118.93±1181.96)、(1181.44±742.18) cGy,差异均有统计学意义(t=0.826、6.143、5.234,P<0.05);PTV的最小、最大、平均PhD和BED分别为(3615.51±1566.10)、(5505.26±1731.64)、(4984.33±1615.59) cGy和(3500.97±1576.92)、(5672.93±1791.98)、(5047.63±1646.57) cGy,差异均无统计学意义(t=6.953、-2.164、-1.193,均P>0.05).随着剂量曲线的下降,PhD和BED也随之降低,而且相应剂量曲线的BED较PhD更低.结论 从增强靶区控制和脊髓保护的角度,胸部肿瘤精确常规分割放疗有必要进行脊髓的BED评估.%Objective To investigate the necessity and feasibility of evaluation for spinal cord biological effect dose (BED) in clinical radiotherapy on thoracic tumors in the model of conformal or intensity modulated technique and conventional fractionation.Methods From 16 May 2016 to 31 December 2016,30 patients accepting thoracic radiotherapy were selected in the Radio-chemotherapy department of Tangshan City People's Hospital.Radiotherapy plans of these patients were evaluated by the evaluation module of the RTIS treatment plan system,and then the physical dose(PhD) and BED were compared,respectively.After that,the PhD and BED of the spinal cord in different dose curves for 2.0 Gy irradiation 1 and 30 times were calculated by the linear quadratic equation(L-Q model).T test was used for all comparison between groups in statistics.Results The BED curve of the spinal cord was on the left of the PhD curve,and the BED curve of planning target volume(PTV) was on the fight of the PhD curve.In the radiotherapy plans of the 30 patients,for the spinal cord,the minimum maximum,average doses of PhD and BED were (80.41t:274.75),(3398.00±1200.95),(1265.79±762.49) cGy and (74.71±249.34),(3118.93±1181.96),(1181.44±742.18) cGy,separately,the differences of them were significantly(t=0.826,6.143,5.234,all P<0.05).However,for the PTV of target the minimum,maximum,average doses of PhD and BED were (3615.51±1566.10),(5505.26±1731.64),(4984.33±1615.59) cGy and (3500.97±1576.92),(5672.93±1791.98),(5047.63±1646.57) cGy,all of them were no significances in statistics (t=6.953,-2.164,-1.193,all P>0.05).With the decline of the dose curve,the PhD and BED were reducing,and the BED were lower than the PhD in the curve for corresponding dose.Conclusions In the radiotherapy of thoracic tumors,considering potential enhancement of local target control and better spinal cord protection,it is necessary to evaluate the BED of the spinal cord.
    • 龙斌; 周光华; 苏加利; 刘利民; 杨新辉; 施晓焱; 龙君
    • 摘要: 目的 研究大分割三维适形放疗鼻咽癌的放射损伤及疗效.方法 采用倾向性得分匹配法,把105例鼻咽癌患者分成全程常规分割适形放疗组(对照组)和前程常规分割后程大分割三维适形放疗组(研究组),观察放射损伤、近期疗效、远期疗效等.结果 两组急性放射损伤、远期放射损伤差异均无统计学意义(P>0.05),治疗后3个月完全缓解率研究组(88.5%)与对照组(67.9%)对比差异有显著性(χ2=6.471,P<0.05),5年生存率研究组(78.8%)、对照组(60.4%)亦有明显优势(χ2=4.225,P<0.05).结论 前程常规分割联合后程大分割适形放疗用于鼻咽癌患者的近期疗效、远期疗效较好,且放射损伤反应与全程常规分割适形放疗并无明显差异,安全性较好.
    • 汪超; 彭万仁; 汤晓伟; 肖鑫; 刘克
    • 摘要: Objective:To analyze the efficacy and the toxicity of esophageal carcinoma treated with three - dimen-sional conformal radiotherapy. Methods:From January 2009 to June 2012,112 patients over 75 years old with esopha-geal carcinoma treated with three - dimensional conformal radiotherapy(3DCRT)and conventional fraction radiothera-py(CFRT)were retrospectively analyzed. The short - term effects,acute side radioative effects,1,2 - year local con-trol rates and the survival rates were evaluated. Results:The short - term effects of 3DCRT and CFRT were 88. 0%and 73. 4% . The 1 - year local control rates were70. 1% and 56. 7% ,the 2 - year local control rates were 32. 8%and 25. 4% . The 1 - year overall survival rates were 58 . 2 % and 44 . 8 % ,the 2 - year overall survival rates were 35. 8% and 25. 3% . The acute side radioative effects in the two groups were similar. Conclusion:For patients o-ver 75 years old with esophageal carcinoma,the efficacy of three - dimensional conformal radiotherapy is superior to conventional fraction radiotherapy and the toxicities can be tolerated.%目的:探讨三维适形放疗对75岁以上老年食管癌患者的疗效及毒副反应。方法:回顾性分析我院自2009年1月至2012年7月接受根治性三维适形放疗(three - dimensional conformal radiotherapy,3DCRT)和常规分割放疗(conventional fraction radiotherapy,CFRT)的112例75岁以上老年食管鳞癌患者临床资料,对比分析两组近期有效率,1、2年局部控制率及生存率,毒副反应。结果:3DCRT 组、CFRT 组近期有效率分别为86.5%和68.8%,1年局部控制率分别为76.1%和53.3%。2年局部控制率分别为46.3%和24.4%,1年生存率分别为79.1%和64.4%,2年生存率分别为49.3%和28.9%。治疗毒副反应相似。结论:75岁以上老年食管癌患者行三维适形放疗疗效优于常规分割放疗,不良反应可耐受。
    • 袁倩倩; 张开贤; 胡苗苗; 吴林霖; 张旭升
    • 摘要: 目的:观察胸部放疗不同分割模式治疗局限期中Ⅲ期小细胞肺癌的疗效及不良反应。方法45例局限期中Ⅲ期小细胞肺癌患者的临床资料,其中超分割放疗 DT 45 Gy 组22例,常规分割放疗 DT 60 Gy 组23例。均采用 EP方案化疗联合放疗,超分割组,1.5 Gy/次,2次/ d,间隔≥6 h,5 d/周,总剂量 DT 45 Gy。常规分割组,2.0 Gy/次,1次/ d,5 d/周,放疗至40 Gy 时缩野加量照射,总剂量 DT 56~60 Gy。对两组的近期有效率,1、2年生存率,放疗不良反应情况进行统计学分析。结果超分割组与常规分割组的近期有效率分别为81.8%和91.3%;1、2年生存率分别为70.7%、35.7%和90.9%、27.9%,差异无统计学意义( P ﹥0.05);中位生存期分别为20个月和20个月。超分割组2级以上放射性食管炎及急性放射性肺炎、3级以上血液学毒性发生率均较常规分割组高。结论超分割放疗与常规分割组治疗局限期中Ⅲ期小细胞肺癌近、远期疗效相似,但超分割组不良反应高,建议对于局限期中Ⅲ期 SCLC 使用常规分割放疗同步化疗。%Objective To observe the efficacy and adverse reactions of thoracic radiation therapy in different segmentation model for limit-ed stage of small cell lung cancer of stage Ⅲ. Methods The clinical data of 45 patients with limited stage of small cell lung cancer patients in stage Ⅲ,including 22 cases of group DT 45 Gy of the hyperfractionated radiotherapy,23 cases of group DT 60 Gy of conventional radiotherapy. EP regimen are used in combination with radiotherapy,hyperfractionated group,1. 5 Gy/ times,2 times / d,spacing ≥6 h,5 d/ week,total dose DT 45 Gy,conventional fractionation group,2. 0 Gy/ times,1 times/ d,5 d/ week,when the shrinking field radiotherapy to 40 Gy irradiation dos-age,the total dose DT 56 ~ 60 Gy. The short - term efficiency of the two groups and 1,2 - year survival rates were statistically analyzed. Results The recent efficiency(CR + PR)of hyper - fractionation group and conventional fractionation were 81. 8% and 91. 3% . 1,2 year survival rates were 70. 7% ,35. 7% and 90. 9% ,27. 9%( P = 0. 942)respectively. The median survival time was 20 and 20 months respectively. The inci-dence rate of radiation esophagitis,pneumonia and bone marrow suppression of hyper - fractionation group was higher than conventional fractiona-tion group. Conclusion Short - term and long - term clinical effects of hyperfractionated radiotherapy and conventional fractionation in the treat-ment of limited stage of phase III SCLC are similar,but the rate of adverse reaction of hyper - fractionation group is higher. Thus the authors sug-gest to use concurrent chemotherapy of the conventional radiotherapy for the limitation period of stage Ⅲ SCLC.
    • 韩红梅
    • 摘要: 本文通过探讨大分割与常规分割三维适形放疗治疗合并上腔静脉压迫综合征的非小细胞肺癌的疗效及临床安全性,得出结论:大分割放射治疗可迅速缓解非小细胞肺癌患者上腔静脉压迫综合征的临床症状,近期疗效优于常规分割组,毒副反应总体看并未见明显增加,也未明显降低患者生存率,临床可根据患者个体差异选择适当的治疗方式,建议病情较重、活动不便的老年患者行大分割放射治疗。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号